Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

Jonathan R. Strosberg,Edward M. Wolin,Beth Chasen,Matthew H. Kulke,David L. Bushnell,M. Caplin,Richard P. Baum,Timothy James Hobday,A. Hendifar,Kjell Öberg,P. Ruszniewski,E. P. Krenning

Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

2018

Jonathan R. Strosberg
Edward M. Wolin
Beth Chasen
Matthew H. Kulke
David L. Bushnell
M. Caplin
Richard P. Baum
Timothy James Hobday
A. Hendifar
Kjell Öberg
P. Ruszniewski
E. P. Krenning

Selected For Oral Presentation: Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study : 177Lu-Dotatate Vs. High Dose Octreotide In Progressive Midgut Neuroendocrine Tumors

Keywords:

177Lu-DOTATATE
Midgut
Endocrinology
Internal medicine
Progression-free survival
Diabetes mellitus
Oncology
Octreotide
Neuroendocrine tumors
Quality of life
Biology
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations